Remetinostat is primarily used in the treatment of cutaneous T-cell lymphoma (CTCL), a type of non-Hodgkin lymphoma that affects the skin. It functions as a histone deacetylase (HDAC) inhibitor, which helps regulate gene expression and can induce cancer cell death. The compound is applied topically, making it a convenient option for targeting skin lesions directly while minimizing systemic side effects. Its localized action is particularly beneficial for patients with early-stage CTCL, offering a non-invasive treatment alternative to systemic therapies. Clinical studies have shown promising results in reducing lesion size and improving skin symptoms, making it a potential therapeutic option for managing this condition.